TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02331511

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administration for 3 months after device(PPM,ICD,CRT) implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 80 mg daily
Description: Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg daily
Description: Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
Study: NCT04291014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SunRay Light Boxes
Description: SunRay light boxes will be used to administer the light therapy.
Study: NCT00948792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short platelet transfusion
Description: 15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long platelet transfusion
Description: 15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
Study: NCT00284518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
Study: NCT02739477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results.
Study: NCT01269125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: single injection of 3.75 leuprolide every 28 days, 3 dosages
Study: NCT00284518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
Study: NCT03574051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
Study: NCT01212276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-028
Description: Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
Study: NCT01269125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: single injection of 3.75 leuprolide every 28 days, 3 dosages

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Assisted Reproduction Technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Assisted Reproduction Technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Assisted Reproduction Technique.
Study: NCT02625519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urinary follicle-stimulating hormone
Description: Ovarian stimulation with highly purified urinary follicle-stimulating hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone
Description: Controled ovarian stimulation with recombinant follicle-stimulating hormone
Study: NCT03411733

Intervention type: OTHER
Intervention: Blood and stool samples collection
Description: Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection

Intervention type: OTHER
Intervention: Blood and stool samples collection
Description: Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
Study: NCT02021422

Intervention type: DRUG
Group type: OTHER
Intervention: anakinra
Description: Dosage Route Administration 100 mg SC Every Other Day

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 2-4 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 180 mg/m2 90 minutes

Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Description: fluorouracil 2400 mg/m2 48 hours
Study: NCT04628871

Intervention type: BIOLOGICAL
Intervention: SB-318
Description: No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.

Intervention type: BIOLOGICAL
Intervention: SB-913
Description: No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
Study: NCT02422147

Intervention type: PROCEDURE
Intervention: Ablation of PCL
Description: All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
Study: NCT01212276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-028
Description: Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-028
Description: Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
Study: NCT03805633

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample
Description: Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample
Description: Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
Study: NCT02596490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and Discussion Sessions
Description: Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped.
Study: NCT03805633

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample
Description: Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of pancreas
Description: Ultrasound of pancreas will be obtained on all study participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of pancreas
Description: Ultrasound of pancreas will be obtained on all study participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of pancreas
Description: Ultrasound of pancreas will be obtained on all study participants.
Study: NCT02272335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Sessions
Description: 10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Sessions
Description: 10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain
Study: NCT04249765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessing grasping force, pinch force,
Description: Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table.
Study: NCT03181386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran and Apixaban
Description: Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
Study: NCT04627844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate Feeding
Description: Standard tube feeds begun at an earlier time point

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Feeding
Description: Standard tube feeds begun at delayed time point
Study: NCT03415867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
Study: NCT02749604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ejaculatory sparring PVP
Description: Greenlight laser photoslective vaporization of the prostate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ejaculatory sparring PVP
Description: Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
Study: NCT00577655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo HFA MDI four times a day (q.i.d) for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proventil® HFA
Description: Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proventil® HFA
Description: Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
Study: NCT02054819

Intervention type: OTHER
Group type: OTHER
Intervention: Induction chemotherapy and concurrent radiation
Description: Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions

Intervention type: OTHER
Group type: OTHER
Intervention: Consolidation: Radiation therapy to metastatic sites
Description: At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
Study: NCT01159145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H
Description: Oral, capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral, tablet
Study: NCT02596490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and Discussion Sessions
Description: Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped.
Study: NCT00712816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Ready Injury Treatment System (CoolSystems Inc.)
Description: Cold with intermittent compression postoperatively for 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice with compressive bandages
Description: Cold with static compression postoperatively for 2 weeks
Study: NCT02244190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: New oral solution (back up) formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tipranavir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT02596490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and Discussion Sessions
Description: Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer-Related Discussion Program
Description: Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
Study: NCT04506775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViTrack
Description: ViTrack is a continuous non-invasive wearable blood pressure cuff.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization
Description: Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
Study: NCT00748722

Intervention type: DEVICE
Intervention: CT Angiography
Description: Injection of contrast material (iodine)
Study: NCT06720012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient specific instrumentation (PSI)
Description: Cutting guides that are manufactured using advanced imaging and modelling techniques to create instruments that align more closely with the unique anatomy of each patient. Custom guides were created based on a preoperative MRI protocol (Zimmer Patient Specific Instrumentation for NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States in collaboration with Materialise NV, Leuven, Belgium) to optimize the placement of the components without the need for intramedullary alignment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional instruments
Description: Instruments specific to the implant that are used to guide bone cutting in reference to the intramedullary canal or using an extramedullary jig.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Total Knee Arthroplasty
Description: A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cemented Total Knee Arthroplasty
Description: A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.
Study: NCT01956318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crenobalneotherapy
Description: 18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
Study: NCT00870116

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT by cyberknife
Description: treatment = 2x15 Gy during 2 weeks

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT by linear accelerator
Description: treatment = 2x15 Gy during 2 weeks

Intervention type: RADIATION
Group type: OTHER
Intervention: Conformational radiotherapy
Description: treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
Study: NCT00627744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
Study: NCT06322485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-management intervention
Description: An internet-based cognitive-behavioral therapy with six modules.
Study: NCT04341883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1+Albumin-Bound Paclitaxel
Description: anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody
Study: NCT04492930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 14:10 Regimen
Description: 14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12:12 Regimen
Description: 12 hours of fasting, followed by a 12-h diet regimen
Study: NCT00503867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres microspheres
Description: SIR-Spheres Yttrium-90 microspheres
Study: NCT01754935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: 50 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: 50 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: 50 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-509 matching placebo
Description: 0 mg oral tablet